ClinicalTrials.gg
CompletedNCT03933449Updated Mar 29, 2023Results posted

Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study

A Phase 3 interventional study of pembrolizumab and paclitaxel in Esophageal Carcinoma and Esophagogastric Junction Carcinoma, sponsored by Merck Sharp & Dohme LLC. Completed at 23 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-29.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 4 months after the study started (first participant enrolled Dec 2016, registered Apr 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
123
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing pembrolizumab in Esophageal Neoplasms — 6 open to participants now, 6 under way, none of them phase 3. pembrolizumab · Esophageal Neoplasms.

Enrollment
6th of 19
123 · median 49
Started
2016
with 2 others
Phase 3
4 of 19
none open now
Registered
10th of 19
by date
Lead sponsor
5 of 19
Merck Sharp & Dohme LLC

Among the 19 studies testing pembrolizumab in Esophageal Neoplasms, this one is the 6th largest by enrollment, is one of 3 that started in 2016, is one of 4 in phase 3, and was the 10th registered.

Esophageal Neoplasms

1,874 studies on the registry are indexed under Esophageal Neoplasms; 503 are open to participants now.

Browse Esophageal Neoplasms studies →

Open to participants now

6 of the 19 studies testing pembrolizumab in Esophageal Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 388 Esophageal Neoplasms studies recruiting now, 246 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing pembrolizumab in Esophageal Neoplasms, or all of them as a file.
02

Study summary

In the China extension study, Chinese participants with advanced or metastatic adenocarcinoma or squamous cell carcinoma of the esophagus or Siewert type I adenocarcinoma of the esophagogastric junction (EGJ) that has progressed after first-line standard therapy will be randomized to receive either single agent pembrolizumab or the Investigator's choice of chemotherapy with paclitaxel, docetaxel, or irinotecan.

The primary extension study hypothesis is that treatment with pembrolizumab will prolong overall survival (OS) as compared to treatment with chemotherapy.

Read the detailed description

The China extension study will include participants previously enrolled in China in the global study for MK-3475-181 (NCT02564263) plus those enrolled during the China extension enrollment period.

Per protocol, response/progression or adverse events during the second pembrolizumab course will not be counted towards efficacy outcome measures or safety outcome measures.

03

Conditions studied

  • Esophageal Carcinoma
  • Esophagogastric Junction Carcinoma

Keywords

  • Programmed Cell Death-1 (PD1, PD-1)
  • Programmed Death-Ligand 1 (PDL1, PD-L1)
  • Programmed Death-Ligand 2 (PDL2, PD-L2)
  • Gene expression profiling (GEP)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • - or cytologically-confirmed diagnosis of adenocarcinoma or squamous cell carcinoma of the esophagus or Siewert type I adenocarcinoma of the EGJ
  • disease or locally advanced, unresectable disease
  • of greater than 3 months
  • based on (RECIST) 1.1
  • Performance status of 0 or 1 on the (ECOG) Performance Scale
  • Documented radiographic or clinical disease progression on no more or less than one previous line of standard therapy
  • Can provide either a newly obtained or sample for intra-tumoral immune-related testing and for anti-programmed cell death (PD)-1
  • Participants of must be willing to use adequate for the course of the study through 120 days after the last dose of pembrolizumab or through 180 days after the last dose of paclitaxel, docetaxel or irinotecan
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Currently participating and receiving study therapy or has participated in a study of an agent and received study therapy or used an investigational device within 4 weeks of the first dose of study medication
  • Active disease that has required systemic treatment in past 2 years
  • Diagnosis of immunodeficiency or receiving systemic therapy or any other form of therapy within 7 days prior to the first dose of study medication
  • Known central nervous system (CNS) and/or carcinomatous meningitis (includes past history or current metastasis)
  • Has received prior anti-cancer monoclonal antibody (mAb), chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or not recovered from adverse events due to a previously administered agent
  • Has had a severe reaction to treatment with another mAb
  • Prior therapy with a , anti-PD-Ligand 1 (PD-L1), or anti-PD-L2 agent, or previously participated in Merck pembrolizumab (MK-3475) study
  • Has a known additional that has progressed or required active treatment within the last 5 years with the exception of curatively treated basal cell and squamous cell carcinoma of the skin and/or curatively resected in-situ cervical and/or breast cancers, and in-situ or intra-mucosal pharyngeal cancer
  • Received a within 30 days of the first dose of study medication
  • Known history of (HIV) infection
  • Known history of or is positive for (hepatitis B surface antigen reactive) or known active [hepatitis C virus ribonucleic acid (RNA) or hepatitis C antibody is detected]
  • History of non-infectious pneumonitis that required steroids or current pneumonitis
  • Active infection requiring systemic therapy
  • Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study
  • Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the study starting with the screening visit through 120 days after the last dose of pembrolizumab or through 180 days after the last dose of paclitaxel, docetaxel or irinotecan
  • Known allergy, hypersensitivity, or to paclitaxel, docetaxel, or irinotecan or any components used in their preparation
  • Experienced weight loss > 10% over \~2 months prior to first dose of study therapy
  • Has ascites or pleural effusion by physical exam
  • Has experienced documented objective radiographic or clinical disease progression during or after receiving more than 1 .
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
123 participants (actual)

Study arms

  • Experimental
    Pembrolizumab

    Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of every 21-day (3-week) cycle for up to 35 administrations (up to \~2 years). Participants who complete the first course of up to 35 administrations of pembrolizumab (\~2 years) but progress after discontinuation, may be eligible for a second course of pembrolizumab at the investigator's discretion, at the same dose and schedule at 200 mg IV on Day 1 of each 3-week cycle for up to 17 cycles (up to \~1 year).

    Biological: pembrolizumab

  • Active comparator
    Chemotherapy

    Participants receive Investigator's choice of chemotherapy: paclitaxel 80-100 mg/m\^2 IV on Days 1, 8, and 15 of every 28-day (4-week) cycle, OR docetaxel 75 mg/m\^2 IV on Day 1 of every 21-day (3-week) cycle, OR irinotecan 180 mg/m\^2 IV on Day 1 of every 14-day (2-week) cycle (up to \~2 years).

    Drug: paclitaxel · Drug: docetaxel · Drug: irinotecan

Interventions

  • Biologicalpembrolizumab

    IV infusion

    Also known as: KEYTRUDA®, MK-3475

  • IV infusion

    Also known as: TAXOL®

  • IV infusion

    Also known as: TAXOTERE®

  • IV infusion

    Also known as: CAMPTOSAR®

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS) in All Participants

    OS was defined as the time from randomization to death due to any cause. Median OS for the first pembrolizumab course in all participants is presented.

    Time frame: From randomization through final analysis data cutoff date of 13-Feb-2019 (Up to ~24 months)

  2. Overall Survival (OS) in Participants With Programmed Death-Ligand 1 Combined Positive Score ≥10 (PD-L1 CPS ≥10)

    OS was defined as the time from randomization to death due to any cause. Median OS for the first pembrolizumab course in participants with a PD-L1 CPS ≥10 is presented.

    Time frame: From randomization through final analysis data cutoff date of 13-Feb-2019 (Up to ~24 months)

  3. Overall Survival (OS) in Participants With Squamous Cell Carcinoma (SCC) of the Esophagus

    OS was defined as the time from randomization to death due to any cause. Median OS for the first pembrolizumab course in participants with SCC of the esophagus is presented.

    Time frame: From randomization through final analysis data cutoff date of 13-Feb-2019 (Up to ~24 months)

Secondary outcomes

  1. Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in All Participants

    ORR was defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) as assessed using RECIST 1.1 by central imaging vendor review. The percentage of all participants who experienced a CR or PR for the first pembrolizumab course is presented.

    Time frame: From randomization through final analysis data cutoff date of 13-Feb-2019 (Up to ~24 months)

  2. Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Participants With Programmed Death-Ligand 1 Combined Positive Score ≥10 (PD-L1 CPS ≥10)

    ORR was defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) as assessed using RECIST 1.1 by central imaging vendor review. The percentage of participants with a PD-L1 CPS ≥10 who experienced a CR or PR for the first pembrolizumab course is presented.

    Time frame: From randomization through final analysis data cutoff date of 13-Feb-2019 (Up to ~24 months)

  3. Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Participants With Squamous Cell Carcinoma (SCC) of the Esophagus

    ORR was defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) as assessed using RECIST 1.1 by central imaging vendor review. The percentage of participants with SCC of the esophagus who experienced a CR or PR for the first pembrolizumab course is presented.

    Time frame: From randomization through final analysis data cutoff date of 13-Feb-2019 (Up to ~24 months)

  4. Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in All Participants

    PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. Median PFS for the first pembrolizumab course as assessed by central imaging vendor review per RECIST 1.1 in all participants is presented.

    Time frame: From randomization through final analysis data cutoff date of 13-Feb-2019 (Up to ~24 months)

  5. Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Participants With Programmed Death-Ligand 1 Combined Positive Score ≥10 (PD-L1 CPS ≥10)

    PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. Median PFS for the first pembrolizumab course as assessed by central imaging vendor review per RECIST 1.1 is presented for participants with a PD-L1 CPS ≥10.

    Time frame: From randomization through final analysis data cutoff date of 13-Feb-2019 (Up to ~24 months)

  6. Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Participants With Squamous Cell Carcinoma (SCC) of the Esophagus

    PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. Median PFS for the first pembrolizumab course as assessed by central imaging vendor review per RECIST 1.1 is presented for participants with SCC of the esophagus.

    Time frame: From randomization through final analysis data cutoff date of 13-Feb-2019 (Up to ~24 months)

  7. Number of Participants Experiencing an Adverse Event (AE)

    An AE was defined as any untoward medical occurrence in a participant administered a study treatment and which does not necessarily have to have a causal relationship with this treatment. The number of participants who experienced ≥1 AE for the first pembrolizumab course are presented.

    Time frame: From randomization through final analysis data cutoff date of 13-Feb-2019 (Up to ~24 months)

  8. Number of Participants Discontinuing Study Treatment Due an Adverse Event (AE)

    An AE was defined as any untoward medical occurrence in a participant administered a study treatment and which does not necessarily have to have a causal relationship with this treatment. The number of participants who discontinued study treatment due to an AE for the first pembrolizumab course are presented.

    Time frame: From randomization through final analysis data cutoff date of 13-Feb-2019 (Up to ~24 months)

07

Results

Posted Feb 26, 2020

Participant flow

Participant flow — Overall Study
MilestonePembrolizumabChemotherapy
Started6261
Treated6259
Received second course10
Discontinued6261
Completed00
Not completed6261
Withdrew: Adverse event64
Withdrew: Death5557
Withdrew: Sponsor decision10

Outcome measures

PrimaryOverall Survival (OS) in All Participants

OS was defined as the time from randomization to death due to any cause. Median OS for the first pembrolizumab course in all participants is presented.

Time frame:
From randomization through final analysis data cutoff date of 13-Feb-2019 (Up to ~24 months)
Reported as:
Median · Months
Overall Survival (OS) in All Participants
MonthsPembrolizumabChemotherapy
Overall Survival (OS) in All Participants8.4 (5.8 to 10.9)5.6 (4.5 to 7.3)
Statistical analysis
  • Pembrolizumab vs Chemotherapy · Log Rank · p = 0.0015 (One-sided p-value based on log-rank test) · Hazard ratio (hr): 0.55 · 95% CI 0.36 to 0.82Based on Cox regression model with treatment as a covariate
PrimaryOverall Survival (OS) in Participants With Programmed Death-Ligand 1 Combined Positive Score ≥10 (PD-L1 CPS ≥10)

OS was defined as the time from randomization to death due to any cause. Median OS for the first pembrolizumab course in participants with a PD-L1 CPS ≥10 is presented.

Time frame:
From randomization through final analysis data cutoff date of 13-Feb-2019 (Up to ~24 months)
Reported as:
Median · Months
Overall Survival (OS) in Participants With Programmed Death-Ligand 1 Combined Positive Score ≥10 (PD-L1 CPS ≥10)
MonthsPembrolizumabChemotherapy
Overall Survival (OS) in Participants With Programmed Death-Ligand 1 Combined Positive Score ≥10 (PD-L1 CPS ≥10)12.0 (6.6 to NA)5.3 (4.1 to 8.2)
Statistical analysis
  • Pembrolizumab vs Chemotherapy · Log Rank · p = 0.0008 (One-sided p-value based on log-rank test) · Hazard ratio (hr): 0.34 · 95% CI 0.17 to 0.69Based on Cox regression model with treatment as a covariate
PrimaryOverall Survival (OS) in Participants With Squamous Cell Carcinoma (SCC) of the Esophagus

OS was defined as the time from randomization to death due to any cause. Median OS for the first pembrolizumab course in participants with SCC of the esophagus is presented.

Time frame:
From randomization through final analysis data cutoff date of 13-Feb-2019 (Up to ~24 months)
Reported as:
Median · Months
Overall Survival (OS) in Participants With Squamous Cell Carcinoma (SCC) of the Esophagus
MonthsPembrolizumabChemotherapy
Overall Survival (OS) in Participants With Squamous Cell Carcinoma (SCC) of the Esophagus8.4 (5.8 to 10.9)5.6 (4.5 to 7.3)
Statistical analysis
  • Pembrolizumab vs Chemotherapy · Log Rank · p = 0.0021 (One-sided p-value based on log-rank test) · Hazard ratio (hr): 0.55 · 95% CI 0.37 to 0.83Based on Cox regression model with treatment as a covariate
SecondaryObjective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in All Participants

ORR was defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) as assessed using RECIST 1.1 by central imaging vendor review. The percentage of all participants who experienced a CR or PR for the first pembrolizumab course is presented.

Time frame:
From randomization through final analysis data cutoff date of 13-Feb-2019 (Up to ~24 months)
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in All Participants
Percentage of ParticipantsPembrolizumabChemotherapy
Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in All Participants16.1 (8.0 to 27.7)3.3 (0.4 to 11.3)
Statistical analysis
  • Pembrolizumab vs Chemotherapy · Miettinen & Nurminen method · p = 0.0084 (One-sided p-value for testing. H0: difference in %=0 versus H1: difference in %\>0.) · Difference in percentages: 12.9 · 95% CI 2.7 to 24.5
SecondaryObjective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Participants With Programmed Death-Ligand 1 Combined Positive Score ≥10 (PD-L1 CPS ≥10)

ORR was defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) as assessed using RECIST 1.1 by central imaging vendor review. The percentage of participants with a PD-L1 CPS ≥10 who experienced a CR or PR for the first pembrolizumab course is presented.

Time frame:
From randomization through final analysis data cutoff date of 13-Feb-2019 (Up to ~24 months)
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Participants With Programmed Death-Ligand 1 Combined Positive Score ≥10 (PD-L1 CPS ≥10)
Percentage of ParticipantsPembrolizumabChemotherapy
Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Participants With Programmed Death-Ligand 1 Combined Positive Score ≥10 (PD-L1 CPS ≥10)24.0 (9.4 to 45.1)6.9 (0.8 to 22.8)
Statistical analysis
  • Pembrolizumab vs Chemotherapy · Miettinen & Nurminen method · p = 0.0403 (One-sided p-value for testing. H0: difference in %=0 versus H1: difference in %\>0.) · Difference in percentages: 17.1 · 95% CI -2.3 to 38.0
SecondaryObjective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Participants With Squamous Cell Carcinoma (SCC) of the Esophagus

ORR was defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) as assessed using RECIST 1.1 by central imaging vendor review. The percentage of participants with SCC of the esophagus who experienced a CR or PR for the first pembrolizumab course is presented.

Time frame:
From randomization through final analysis data cutoff date of 13-Feb-2019 (Up to ~24 months)
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Participants With Squamous Cell Carcinoma (SCC) of the Esophagus
Percentage of ParticipantsPembrolizumabChemotherapy
Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Participants With Squamous Cell Carcinoma (SCC) of the Esophagus16.7 (8.3 to 28.5)3.4 (0.4 to 11.7)
Statistical analysis
  • Pembrolizumab vs Chemotherapy · Miettinen & Nurminen method · p = 0.0083 (One-sided p-value for testing. H0: difference in %=0 versus H1: difference in %\>0.) · Difference in percentages: 13.3 · 95% CI 2.8 to 25.2
SecondaryProgression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in All Participants

PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. Median PFS for the first pembrolizumab course as assessed by central imaging vendor review per RECIST 1.1 in all participants is presented.

Time frame:
From randomization through final analysis data cutoff date of 13-Feb-2019 (Up to ~24 months)
Reported as:
Median · Months
Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in All Participants
MonthsPembrolizumabChemotherapy
Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in All Participants2.5 (2.1 to 4.1)2.8 (2.0 to 4.2)
Statistical analysis
  • Pembrolizumab vs Chemotherapy · Log Rank · p = 0.177 (One-sided p-value based on log-rank test) · Hazard ratio (hr): 0.84 · 95% CI 0.58 to 1.23Based on Cox regression model with treatment as a covariate
SecondaryProgression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Participants With Programmed Death-Ligand 1 Combined Positive Score ≥10 (PD-L1 CPS ≥10)

PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. Median PFS for the first pembrolizumab course as assessed by central imaging vendor review per RECIST 1.1 is presented for participants with a PD-L1 CPS ≥10.

Time frame:
From randomization through final analysis data cutoff date of 13-Feb-2019 (Up to ~24 months)
Reported as:
Median · Months
Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Participants With Programmed Death-Ligand 1 Combined Positive Score ≥10 (PD-L1 CPS ≥10)
MonthsPembrolizumabChemotherapy
Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Participants With Programmed Death-Ligand 1 Combined Positive Score ≥10 (PD-L1 CPS ≥10)4.0 (2.1 to 6.1)4.0 (2.0 to 5.3)
Statistical analysis
  • Pembrolizumab vs Chemotherapy · Log Rank · p = 0.238 (One-sided p-value based on log-rank test) · Hazard ratio (hr): 0.81 · 95% CI 0.44 to 1.46Based on Cox regression model with treatment as a covariate
SecondaryProgression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Participants With Squamous Cell Carcinoma (SCC) of the Esophagus

PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. Median PFS for the first pembrolizumab course as assessed by central imaging vendor review per RECIST 1.1 is presented for participants with SCC of the esophagus.

Time frame:
From randomization through final analysis data cutoff date of 13-Feb-2019 (Up to ~24 months)
Reported as:
Median · Months
Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Participants With Squamous Cell Carcinoma (SCC) of the Esophagus
MonthsPembrolizumabChemotherapy
Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in Participants With Squamous Cell Carcinoma (SCC) of the Esophagus2.3 (2.1 to 4.1)2.8 (2.0 to 4.2)
Statistical analysis
  • Pembrolizumab vs Chemotherapy · Log Rank · p = 0.171 (One-sided p-value based on log-rank test) · Hazard ratio (hr): 0.84 · 95% CI 0.57 to 1.23Based on Cox regression model with treatment as a covariate
SecondaryNumber of Participants Experiencing an Adverse Event (AE)

An AE was defined as any untoward medical occurrence in a participant administered a study treatment and which does not necessarily have to have a causal relationship with this treatment. The number of participants who experienced ≥1 AE for the first pembrolizumab course are presented.

Time frame:
From randomization through final analysis data cutoff date of 13-Feb-2019 (Up to ~24 months)
Reported as:
Count of participants · Participants
Number of Participants Experiencing an Adverse Event (AE)
ParticipantsPembrolizumabChemotherapy
Number of Participants Experiencing an Adverse Event (AE)6256
SecondaryNumber of Participants Discontinuing Study Treatment Due an Adverse Event (AE)

An AE was defined as any untoward medical occurrence in a participant administered a study treatment and which does not necessarily have to have a causal relationship with this treatment. The number of participants who discontinued study treatment due to an AE for the first pembrolizumab course are presented.

Time frame:
From randomization through final analysis data cutoff date of 13-Feb-2019 (Up to ~24 months)
Reported as:
Count of participants · Participants
Number of Participants Discontinuing Study Treatment Due an Adverse Event (AE)
ParticipantsPembrolizumabChemotherapy
Number of Participants Discontinuing Study Treatment Due an Adverse Event (AE)109

Adverse events

Collected over From randomization through end-of-trial analysis data cutoff date of 14-March-2022 (Up to ~52 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pembrolizumab First Course61/62 (98.4%)23/62 (37.1%)58/62 (93.5%)
Chemotherapy61/61 (100%)23/59 (39%)55/59 (93.2%)
Pembrolizumab Second Course0/1 (0%)0/1 (0%)1/1 (100%)
Most frequent serious events
Showing 10 of 48
Most frequent serious events
EventPembrolizumab First CourseChemotherapyPembrolizumab Second Course
PneumoniaInfections and infestations3/622/590/1
MyelosuppressionBlood and lymphatic system disorders0/622/590/1
DiarrhoeaGastrointestinal disorders0/622/590/1
Gastrointestinal haemorrhageGastrointestinal disorders0/622/590/1
Oesophageal fistulaGastrointestinal disorders1/622/590/1
White blood cell count decreasedInvestigations0/622/590/1
Suicide attemptPsychiatric disorders0/622/590/1
HaemoptysisRespiratory, thoracic and mediastinal disorders0/622/590/1
DysphagiaGastrointestinal disorders2/620/590/1
Oesophageal obstructionGastrointestinal disorders2/621/590/1
Most frequent other events
Showing 10 of 63
Most frequent other events
EventPembrolizumab First CourseChemotherapyPembrolizumab Second Course
AnaemiaBlood and lymphatic system disorders19/6230/591/1
NauseaGastrointestinal disorders6/6216/591/1
PyrexiaGeneral disorders5/629/591/1
Decreased appetiteMetabolism and nutrition disorders11/6211/591/1
HeadacheNervous system disorders3/621/591/1
White blood cell count decreasedInvestigations4/6228/590/1
VomitingGastrointestinal disorders5/6219/590/1
DiarrhoeaGastrointestinal disorders8/6217/590/1
Neutrophil count decreasedInvestigations2/6217/590/1
Weight decreasedInvestigations13/6216/590/1

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PembrolizumabChemotherapyTotal
Mean60.1 ± 7.059.6 ± 7.059.9 ± 7.0
Sex: Female, Male
Sex: Female, Male(Participants)PembrolizumabChemotherapyTotal
Female538
Male5758115
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PembrolizumabChemotherapyTotal
Hispanic or Latino000
Not Hispanic or Latino6261123
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PembrolizumabChemotherapyTotal
American Indian or Alaska Native000
Asian6261123
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Programmed Death-Ligand 1 (PD-L1) Status: Combined Positive Score (CPS)
Programmed Death-Ligand 1 (PD-L1) Status: Combined Positive Score (CPS)(Participants)PembrolizumabChemotherapyTotal
PD-L1 CPS ≥10252954
PD-L1 CPS <10353166
Not Evaluable213
Tumor Histology
Tumor Histology(Participants)PembrolizumabChemotherapyTotal
Squamous cell carcinoma6059119
Adenocarcinoma of esophagus & EGJ Siewert type I224
08

Study locations

23 sites
  • Anhui Provincial Hospital ( Site 0708)
    Hefei, Anhui 230001, China
  • The First Affiliated Hospital of Anhui Medical University ( Site 0707)
    Hefei, Anhui 230022, China
  • Harbin Medical University Cancer Hospital ( Site 0714)
    Harbin, Heilongjiang 150081, China
  • Wuhan Tongji Hospital ( Site 0724)
    Wuhan, Hubei 430030, China
  • Hunan Cancer Hospital ( Site 0722)
    Changsha, Hunan 410013, China
  • Jiangsu Cancer Hospital (Site 0704)
    Nanjing, Jiangsu 210000, China
  • PLA Cancer Centre of Nanjing Bayi Hospital ( Site 0706)
    Nanjing, Jiangsu 210002, China
  • The First Hospital Of Jilin University ( Site 0719)
    Chang chun, Jilin 130021, China
  • Jilin Cancer Hospital ( Site 0718)
    Changchun, Jilin 130012, China
  • Zhejiang Cancer Hospital ( Site 0726)
    Hangzhou, Zhejiang 310022, China
  • Beijing Cancer Hospital ( Site 0700)
    Beijing, 100042, China
  • Chinese PLA General Hospital (Site 0703)
    Beijing, 100042, China
  • Peking Union Medical College Hospital ( Site 0712)
    Beijing, 100730, China
  • Fujian Medical University Union Hospital ( Site 0721)
    Fuzhou, 350001, China
  • Fujian Province Cancer Hospital ( ( Site 0717)
    Fuzhou, 350014, China
  • The Second Affiliated Hospital of Zhejiang University School of Medicine ( Site 0705)
    Hangzhou, 310009, China
  • Sir Sun Sun Shaw Hosp, Zhejiang Univ,Oncology dept. ( Site 0720)
    Hangzhou, 310016, China
  • The Affiliated Hospital of Qingdao University ( Site 0709)
    Qingdao, 266003, China
  • Ruijin Hospital, Shanghai Jiaotong University ( Site 0701)
    Shanghai, 200025, China
  • Shanghai Chest Hospital ( Site 0727)
    Shanghai, 200030, China
  • Fudan University Shanghai Cancer Center ( Site 0723)
    Shanghai, 200032, China
  • Zhongshan Hospital affiliated to Fudan University ( Site 0715)
    Shanghai, 200032, China
  • Henan Cancer Hospital ( Site 0725)
    Zhengzhou, 450008, China
09

References and documents

Publications

  • Cao Y, Qin S, Luo S, Li Z, Cheng Y, Fan Y, Sun Y, Yin X, Yuan X, Li W, Liu T, Hsu CH, Lin X, Kim SB, Kojima T, Zhang J, Lee SH, Bai Y, Muro K, Doi T, Bai C, Gu K, Pan HM, Bai L, Yang JW, Cui Y, Lu W, Chen J. Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia. ESMO Open. 2022 Feb;7(1):100341. doi: 10.1016/j.esmoop.2021.100341. Epub 2021 Dec 29. PubMed 34973513 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Feb 2019, 25 months.

Results were first posted in Feb 2020, 1 year after primary completion.

Of 57 phase 3 interventional studies under Esophageal Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 113. This study's 25 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2019
First posted
May 1, 2019
StartActual
Dec 29, 2016
Primary completionActual
Feb 13, 2019
CompletionActual
Mar 14, 2022
Results first posted
Feb 26, 2020
Last update
Mar 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03933449
Responsible party
Sponsor
First posted
May 1, 2019
Start date
Dec 29, 2016
Primary completion
Feb 13, 2019
Completion
Mar 14, 2022
Results posted
Feb 26, 2020
Last update
Mar 29, 2023

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pembrolizumab

Start the discussion